@conference{6c3c6dbf1fdb425a8c34ea9bea40f25a,
title = "Long-term response in a patient with urothelial cancer (UC) treated with AEZS-108.",
author = "Fernandez, \{Gustavo L.\} and Schally, \{Andrew V.\} and Tulay Koru-Sengul and Merce Jorda and Merchan, \{Jaime R.\} and Flores, \{Aurea M.\} and Block, \{Norman L.\} and Murugesan Manoharan and Juergen Engel",
note = "e15596 Background: AEZS-108 (AN-152, zoptarelin doxorubicin) is an LHRH-cytotoxic hybrid drug consisting of a Luteinizing Hormone Releasing Hormone (LHRH) agonist coupled to the cytotoxic radical, doxorubicin. The binding permits AEZS-108 to accumulate on the surface of cells expressing LHRH receptors (LHRH-R) thus allowing drug uptake.; Journal of Clinical Oncology ; Conference date: 01-01-2020",
year = "2017",
month = jan,
day = "30",
language = "American English",
}